Go Pro
→ The national debt just passed $39 trillion (From US Gold Bureau) (Ad)tc pixel Free ALPS Stock Alerts

ALPS Group Inc Ordinary Share (ALPS) Competitors

$0.40 0.00 (0.00%)
Closing price 09/15/2026 04:00 PM Eastern
Extended Trading
$0.40 0.00 (0.00%)
As of 09/15/2026 05:44 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

ALPS vs. RNAC, MGNX, TRDA, AVXL, and ALEC

Should you buy ALPS Group Inc Ordinary Share stock or one of its competitors? ALPS Group Inc Ordinary Share's main competitors and comparable companies include Cartesian Therapeutics (RNAC), MacroGenics (MGNX), Entrada Therapeutics (TRDA), Anavex Life Sciences (AVXL), and Alector (ALEC). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does ALPS Group Inc Ordinary Share compare to Cartesian Therapeutics?

Cartesian Therapeutics (NASDAQ:RNAC) and ALPS Group Inc Ordinary Share (NASDAQ:ALPS) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, risk, earnings, valuation, analyst recommendations, media sentiment, dividends and institutional ownership.

ALPS Group Inc Ordinary Share has a net margin of 0.00% compared to Cartesian Therapeutics' net margin of -8,550.65%.

Company Net Margins Return on Equity Return on Assets
Cartesian Therapeutics-8,550.65% N/A -29.84%
ALPS Group Inc Ordinary Share N/A N/A N/A

Cartesian Therapeutics has a beta of 0.62, suggesting that its share price is 38% less volatile than the broader market. Comparatively, ALPS Group Inc Ordinary Share has a beta of -0.1, suggesting that its share price is 110% less volatile than the broader market.

87.0% of Cartesian Therapeutics shares are owned by institutional investors. Comparatively, 27.9% of ALPS Group Inc Ordinary Share shares are owned by institutional investors. 37.2% of Cartesian Therapeutics shares are owned by company insiders. Comparatively, 0.8% of ALPS Group Inc Ordinary Share shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

ALPS Group Inc Ordinary Share has higher revenue and earnings than Cartesian Therapeutics. Cartesian Therapeutics is trading at a lower price-to-earnings ratio than ALPS Group Inc Ordinary Share, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cartesian Therapeutics$2.80M85.24-$130.30M-$5.94N/A
ALPS Group Inc Ordinary Share$4.86M13.70-$2.01M$0.331.21

In the previous week, Cartesian Therapeutics and Cartesian Therapeutics both had 1 articles in the media. ALPS Group Inc Ordinary Share's average media sentiment score of 1.89 beat Cartesian Therapeutics' score of 0.93 indicating that ALPS Group Inc Ordinary Share is being referred to more favorably in the news media.

Company Overall Sentiment
Cartesian Therapeutics Positive
ALPS Group Inc Ordinary Share Very Positive

Cartesian Therapeutics presently has a consensus target price of $32.60, indicating a potential upside of 313.18%. Given Cartesian Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Cartesian Therapeutics is more favorable than ALPS Group Inc Ordinary Share.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cartesian Therapeutics
1 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.57
ALPS Group Inc Ordinary Share
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Summary

Cartesian Therapeutics and ALPS Group Inc Ordinary Share tied by winning 7 of the 14 factors compared between the two stocks.

How does ALPS Group Inc Ordinary Share compare to MacroGenics?

MacroGenics (NASDAQ:MGNX) and ALPS Group Inc Ordinary Share (NASDAQ:ALPS) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, media sentiment, risk, dividends and earnings.

ALPS Group Inc Ordinary Share has a net margin of 0.00% compared to MacroGenics' net margin of -8.70%. ALPS Group Inc Ordinary Share's return on equity of 0.00% beat MacroGenics' return on equity.

Company Net Margins Return on Equity Return on Assets
MacroGenics-8.70% -109.26% -18.70%
ALPS Group Inc Ordinary Share N/A N/A N/A

96.9% of MacroGenics shares are held by institutional investors. Comparatively, 27.9% of ALPS Group Inc Ordinary Share shares are held by institutional investors. 13.6% of MacroGenics shares are held by insiders. Comparatively, 0.8% of ALPS Group Inc Ordinary Share shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

MacroGenics presently has a consensus target price of $6.33, suggesting a potential upside of 56.77%. Given MacroGenics' stronger consensus rating and higher probable upside, equities analysts clearly believe MacroGenics is more favorable than ALPS Group Inc Ordinary Share.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
MacroGenics
1 Sell rating(s)
3 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.17
ALPS Group Inc Ordinary Share
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

In the previous week, MacroGenics had 3 more articles in the media than ALPS Group Inc Ordinary Share. MarketBeat recorded 4 mentions for MacroGenics and 1 mentions for ALPS Group Inc Ordinary Share. ALPS Group Inc Ordinary Share's average media sentiment score of 1.89 beat MacroGenics' score of 0.47 indicating that ALPS Group Inc Ordinary Share is being referred to more favorably in the news media.

Company Overall Sentiment
MacroGenics Neutral
ALPS Group Inc Ordinary Share Very Positive

ALPS Group Inc Ordinary Share has lower revenue, but higher earnings than MacroGenics. MacroGenics is trading at a lower price-to-earnings ratio than ALPS Group Inc Ordinary Share, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MacroGenics$149.50M1.72-$74.62M-$0.22N/A
ALPS Group Inc Ordinary Share$4.86M13.70-$2.01M$0.331.21

MacroGenics has a beta of 1.22, meaning that its share price is 22% more volatile than the broader market. Comparatively, ALPS Group Inc Ordinary Share has a beta of -0.1, meaning that its share price is 110% less volatile than the broader market.

Summary

MacroGenics and ALPS Group Inc Ordinary Share tied by winning 8 of the 16 factors compared between the two stocks.

How does ALPS Group Inc Ordinary Share compare to Entrada Therapeutics?

ALPS Group Inc Ordinary Share (NASDAQ:ALPS) and Entrada Therapeutics (NASDAQ:TRDA) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, risk, profitability, earnings, analyst recommendations, media sentiment, institutional ownership and valuation.

ALPS Group Inc Ordinary Share has higher earnings, but lower revenue than Entrada Therapeutics. Entrada Therapeutics is trading at a lower price-to-earnings ratio than ALPS Group Inc Ordinary Share, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ALPS Group Inc Ordinary Share$4.86M13.70-$2.01M$0.331.21
Entrada Therapeutics$25.42M10.54-$143.75M-$3.96N/A

ALPS Group Inc Ordinary Share has a beta of -0.1, suggesting that its share price is 110% less volatile than the broader market. Comparatively, Entrada Therapeutics has a beta of -0.25, suggesting that its share price is 125% less volatile than the broader market.

In the previous week, Entrada Therapeutics had 9 more articles in the media than ALPS Group Inc Ordinary Share. MarketBeat recorded 10 mentions for Entrada Therapeutics and 1 mentions for ALPS Group Inc Ordinary Share. ALPS Group Inc Ordinary Share's average media sentiment score of 1.89 beat Entrada Therapeutics' score of 0.47 indicating that ALPS Group Inc Ordinary Share is being referred to more favorably in the media.

Company Overall Sentiment
ALPS Group Inc Ordinary Share Very Positive
Entrada Therapeutics Neutral

27.9% of ALPS Group Inc Ordinary Share shares are owned by institutional investors. Comparatively, 86.4% of Entrada Therapeutics shares are owned by institutional investors. 0.8% of ALPS Group Inc Ordinary Share shares are owned by company insiders. Comparatively, 9.5% of Entrada Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Entrada Therapeutics has a consensus target price of $17.75, indicating a potential upside of 157.99%. Given Entrada Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Entrada Therapeutics is more favorable than ALPS Group Inc Ordinary Share.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ALPS Group Inc Ordinary Share
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Entrada Therapeutics
1 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.50

ALPS Group Inc Ordinary Share has a net margin of 0.00% compared to Entrada Therapeutics' net margin of -3,537.73%. ALPS Group Inc Ordinary Share's return on equity of 0.00% beat Entrada Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
ALPS Group Inc Ordinary ShareN/A N/A N/A
Entrada Therapeutics -3,537.73%-57.61%-46.54%

Summary

ALPS Group Inc Ordinary Share beats Entrada Therapeutics on 9 of the 16 factors compared between the two stocks.

How does ALPS Group Inc Ordinary Share compare to Anavex Life Sciences?

ALPS Group Inc Ordinary Share (NASDAQ:ALPS) and Anavex Life Sciences (NASDAQ:AVXL) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, risk, valuation, media sentiment, analyst recommendations, profitability, institutional ownership and earnings.

In the previous week, Anavex Life Sciences had 7 more articles in the media than ALPS Group Inc Ordinary Share. MarketBeat recorded 8 mentions for Anavex Life Sciences and 1 mentions for ALPS Group Inc Ordinary Share. ALPS Group Inc Ordinary Share's average media sentiment score of 1.89 beat Anavex Life Sciences' score of 0.15 indicating that ALPS Group Inc Ordinary Share is being referred to more favorably in the media.

Company Overall Sentiment
ALPS Group Inc Ordinary Share Very Positive
Anavex Life Sciences Neutral

ALPS Group Inc Ordinary Share has a beta of -0.1, suggesting that its share price is 110% less volatile than the broader market. Comparatively, Anavex Life Sciences has a beta of 1.14, suggesting that its share price is 14% more volatile than the broader market.

27.9% of ALPS Group Inc Ordinary Share shares are held by institutional investors. Comparatively, 31.6% of Anavex Life Sciences shares are held by institutional investors. 0.8% of ALPS Group Inc Ordinary Share shares are held by company insiders. Comparatively, 11.0% of Anavex Life Sciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

ALPS Group Inc Ordinary Share's return on equity of 0.00% beat Anavex Life Sciences' return on equity.

Company Net Margins Return on Equity Return on Assets
ALPS Group Inc Ordinary ShareN/A N/A N/A
Anavex Life Sciences N/A -11.43%-10.72%

ALPS Group Inc Ordinary Share has higher revenue and earnings than Anavex Life Sciences. Anavex Life Sciences is trading at a lower price-to-earnings ratio than ALPS Group Inc Ordinary Share, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ALPS Group Inc Ordinary Share$4.86M13.70-$2.01M$0.331.21
Anavex Life SciencesN/AN/A-$46.38M-$0.15N/A

Anavex Life Sciences has a consensus price target of $21.33, indicating a potential upside of 774.32%. Given Anavex Life Sciences' stronger consensus rating and higher probable upside, analysts plainly believe Anavex Life Sciences is more favorable than ALPS Group Inc Ordinary Share.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ALPS Group Inc Ordinary Share
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Anavex Life Sciences
1 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.40

Summary

ALPS Group Inc Ordinary Share and Anavex Life Sciences tied by winning 7 of the 14 factors compared between the two stocks.

How does ALPS Group Inc Ordinary Share compare to Alector?

ALPS Group Inc Ordinary Share (NASDAQ:ALPS) and Alector (NASDAQ:ALEC) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, dividends, valuation, earnings, analyst recommendations, media sentiment, risk and institutional ownership.

ALPS Group Inc Ordinary Share has a net margin of 0.00% compared to Alector's net margin of -850.13%. ALPS Group Inc Ordinary Share's return on equity of 0.00% beat Alector's return on equity.

Company Net Margins Return on Equity Return on Assets
ALPS Group Inc Ordinary ShareN/A N/A N/A
Alector -850.13%-531.03%-44.00%

Alector has a consensus price target of $3.63, indicating a potential upside of 77.70%. Given Alector's stronger consensus rating and higher probable upside, analysts plainly believe Alector is more favorable than ALPS Group Inc Ordinary Share.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ALPS Group Inc Ordinary Share
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Alector
2 Sell rating(s)
3 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.13

27.9% of ALPS Group Inc Ordinary Share shares are owned by institutional investors. Comparatively, 85.8% of Alector shares are owned by institutional investors. 0.8% of ALPS Group Inc Ordinary Share shares are owned by insiders. Comparatively, 8.3% of Alector shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

ALPS Group Inc Ordinary Share has a beta of -0.1, meaning that its stock price is 110% less volatile than the broader market. Comparatively, Alector has a beta of 0.65, meaning that its stock price is 35% less volatile than the broader market.

ALPS Group Inc Ordinary Share has higher earnings, but lower revenue than Alector. Alector is trading at a lower price-to-earnings ratio than ALPS Group Inc Ordinary Share, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ALPS Group Inc Ordinary Share$4.86M13.70-$2.01M$0.331.21
Alector$21.05M10.82-$142.93M-$1.10N/A

In the previous week, Alector had 2 more articles in the media than ALPS Group Inc Ordinary Share. MarketBeat recorded 3 mentions for Alector and 1 mentions for ALPS Group Inc Ordinary Share. ALPS Group Inc Ordinary Share's average media sentiment score of 1.89 beat Alector's score of 0.91 indicating that ALPS Group Inc Ordinary Share is being referred to more favorably in the media.

Company Overall Sentiment
ALPS Group Inc Ordinary Share Very Positive
Alector Positive

Summary

ALPS Group Inc Ordinary Share and Alector tied by winning 8 of the 16 factors compared between the two stocks.

Get ALPS Group Inc Ordinary Share News Delivered to You Automatically

Sign up to receive the latest news and ratings for ALPS and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ALPS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ALPS vs. The Competition

Export
MetricALPS Group Inc Ordinary ShareBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$66.56M$3.89B$7.21B$15.01B
Dividend YieldN/A3.65%2.57%12.21%
P/E Ratio1.2114.11272.8425.31
Price / Sales13.701,434.33701.69107.35
Price / CashN/A108.9477.7151.48
Price / Book-0.1315.1710.376.18
Net Income-$2.01M-$22.78M$3.49B$357.96M
7 Day Performance3.90%-0.71%-0.76%-0.56%
1 Month Performance25.00%0.29%-0.39%-3.62%
1 Year PerformanceN/A39.41%18.93%6.05%

ALPS Group Inc Ordinary Share Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ALPS
ALPS Group Inc Ordinary Share
1.0158 of 5 stars		$0.40
flat		N/AN/A$66.56M$4.86M1.21N/A
RNAC
Cartesian Therapeutics
2.4598 of 5 stars		$8.43
-3.0%		$32.60
+286.7%		-19.4%$255.01M$2.80MN/A64
MGNX
MacroGenics
2.1686 of 5 stars		$3.97
-3.4%		$6.33
+59.5%		+159.0%$252.89M$149.50MN/A430
TRDA
Entrada Therapeutics
2.8202 of 5 stars		$6.42
-9.7%		$17.75
+176.5%		+36.0%$250.00M$25.42MN/A110
AVXL
Anavex Life Sciences
1.6276 of 5 stars		$2.66
-3.3%		$21.33
+702.0%		-73.2%$246.58MN/AN/A40

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:ALPS) was last updated on 9/16/2026 by MarketBeat.com Staff.
From Our Partners
This Microcap Is Taking On the Energy Industry’s Dirtiest Problems
A small company has developed water-based cleaning technologies aimed at some of heavy industry's toughest pro...
Wall Street Logic | Sponsoredtc pixel
“This is the Perfect Tech Stock”
Jeff Brown, the tech investor who identified Nvidia in 2016 before its 37,000% run, has flagged a new AI compa...
Brownstone Research | Sponsoredtc pixel
Jon Najarian's #1 Energy Trade for 2026
Jon Najarian says he's never been more excited about an energy opportunity. SpaceX just went public at over $2...
Banyan Hill Publishing | Sponsoredtc pixel
A “bloodbath” Is Coming
Reports suggest some Silicon Valley billionaires are stockpiling gold, guns, and gas masks - or leaving the co...
TradeSmith | Sponsoredtc pixel
The national debt just passed $39 trillion
The U.S. national debt just topped $39 trillion, up nearly $3 trillion in a single year and on pace to hit $40...
US Gold Bureau | Sponsoredtc pixel
You’ve never seen anything like this before
For centuries, families like the Rothschilds, Morgans, and Rockefellers have quietly used one overlooked type ...
Porter & Company | Sponsoredtc pixel
Why major institutions are piling into this digital asset now
BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...
Awesomely | Sponsoredtc pixel
Your book attached
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...
Profits Run | Sponsoredtc pixel